WILMINGTON, Del.–(BUSINESS WIRE)–Rigrodsky & Long, P.A.:
- Do you own shares of Corium International, Inc. (NASDAQ GM: CORI)?
- Did you purchase any of your shares prior to October 11, 2018?
- Do you think the proposed buyout is fair?
- Do you want to discuss your rights?
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Corium International, Inc. (“Corium” or the “Company”) (NASDAQ GM: CORI) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Gurnet Point Capital (“GPC”) in a transaction valued at approximately $504 million. Under the terms of the agreement, shareholders of Corium will receive $12.50 per share in cash upon the closing. The agreement also provides for a Contingent Value Right of $0.50 per share that is payable based on the U.S. Food and Drug Administration’s approval of Corium’s lead product candidate, Corplex Donepezil, for the treatment of Alzheimer’s disease, prior to March 31, 2020.
If you own common stock of Corium and purchased any shares before October 11, 2018, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra toll-free at (888) 969-4242, by e-mail at firstname.lastname@example.org, or at https://www.rigrodskylong.com/offices-contact.
Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.
Attorney advertising. Prior results do not guarantee a similar outcome.